Asset Details
Do you wish to reserve the book?
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease
Do you wish to request the book?
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Getting Under the Skin: Targeting Cutaneous Autoimmune Disease
2020
Overview
Autoimmune diseases of the skin occur when the immune system attacks normal skin. The immune system can be broadly divided into an effector arm responsible for fighting infections and cancer and a regulatory arm that reduces autoreactivity and maintains immune homeostasis. Cutaneous autoimmunity develops when the equilibrium between the effector arm and regulatory arm of the immune system is disrupted. Recent insights into the inflammatory pathways that are overactive in some cutaneous autoimmune diseases have led to therapies targeting the effector arm of the immune system with greater treatment efficacy than previously used broad immunosuppressants. The current paradigm of inhibiting excessive immune activation for treating cutaneous autoimmunity will be discussed including cytokine blockade, cellular depletion, intracellular signaling blockade and costimulatory blockade. Despite the success of this approach many cutaneous autoimmune diseases lack a clearly delineated pathway to target and therefore new strategies are needed. An emerging therapeutic strategy targeting the regulatory arm of the immune system to induce tolerance and disease remission provides new hope for treating cutaneous autoimmunity. Such an approach includes cellular therapy with regulatory T cells and chimeric autoantibody receptor T cells, cytokine therapy with low-dose interleukin-2, immune checkpoint stimulation, tolerogenic vaccines and microbiome biotherapy. This mini-review will discuss the current and emerging therapeutic strategies for cutaneous autoimmune diseases and provide an organizational framework for understanding distinct mechanisms of action.
Publisher
Yale Journal of Biology and Medicine,YJBM
Subject
/ Antigens
/ Autoimmune Diseases - drug therapy
/ Autoimmune Diseases - immunology
/ Baldness
/ Humans
/ Immune System - drug effects
/ Kinases
/ Molecular Targeted Therapy - methods
/ Molecular Targeted Therapy - trends
/ Peptides
/ Signal Transduction - drug effects
/ Skin Diseases - drug therapy
/ Vitiligo
